{"name":"Napp Pharmaceuticals Limited","slug":"napp-pharmaceuticals-limited","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Codeine paracetamol","genericName":"Codeine paracetamol","slug":"codeine-paracetamol","indication":"Moderate acute pain","status":"marketed"}]}],"pipeline":[{"name":"Codeine paracetamol","genericName":"Codeine paracetamol","slug":"codeine-paracetamol","phase":"marketed","mechanism":"Codeine acts as a weak opioid agonist while paracetamol inhibits prostaglandin synthesis, together providing analgesic and antipyretic effects.","indications":["Moderate acute pain","Mild to moderate chronic pain"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTE13d0Y1OGNyZUdSMVUwVktfRkliOER6SzVVM3lQbXlGM3dPVWhUc3JMZ3ZabzJaZXNsVjNVRnlZVXpzSVgta2dkSGhOSjRESTIwYTB4OWoyUjN2TTg?oc=5","date":"2026-02-26","type":"pipeline","source":"Britannica","summary":"Sackler family | Brothers, OxyContin, Purdue Pharma, Opioid Epidemic, & Mundipharma - Britannica","headline":"Sackler family | Brothers, OxyContin, Purdue Pharma, Opioid Epidemic, & Mundipharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTFA5Si1QMjk0MC1RZkhQWlZ6Z2UyRkRRejhqak41STBLeUFULVN6NXZtdkN2aWwydEFnYlRBZG1uNHpST21VaVFMekp5YXdsc1hYLXNBcFd0RG9DZ3U1dmNVa1BMWmN2NVZYMC1Rbk9iM3RIcU5YSlR3MQ?oc=5","date":"2026-02-21","type":"pipeline","source":"Pharmacy Business","summary":"OxyContin Fallout Casts Shadow Over Napp - Pharmacy Business","headline":"OxyContin Fallout Casts Shadow Over Napp","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxOM29aZG9xTThRSlIyWXlMOHB0TWFmQk9qZ2dwLWhvRE5TREZJNFlTdUpaTkJ3MDNGeTFpZVlUdzJhc19oa19GM09xS1JnWmIxRTAxU250RGY0QWhOakNpY2tWSEFpSUVTdUN4SEtRNXRSRmo1b0lhZTQ4cm5GcUpzbVBNZmpvR2hNenQ1czBWeHRKbUYxMkZta210Y1FEVkJJdVVvbl9HRGRDUWU0VkJyQUt6R1lrZ1RXUW5CbmxhVG9rZTNIOHZZanZ1TExuemRnNmg2OTJXR1RrbGVhd2JMUzJ6aGxmdXIwRktaS1JWTm41YXBlVDBJaUtn?oc=5","date":"2025-10-10","type":"trial","source":"businesswire.com","summary":"Mundipharma announces patient enrolment completion in Phase III ReSPECT clinical trial for REZZAYO® (rezafungin) - businesswire.com","headline":"Mundipharma announces patient enrolment completion in Phase III ReSPECT clinical trial for REZZAYO® (rezafungin)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxNUHh5MWk2aXlRNGN1UVFtUHh4cEcyQVFtOGtmcGItRnhTZkxhWlhLdnNTYmY2Z3J0ek1POC04YWFuWWdBQkV1M1pxTm1IN0ZacGIwcS16RzBaRndCUldlQWxnV0NxRFc5S0xUTksxbUhrY3FaaGVITDlVY1JDYWppLUNKUE9xOWRGVEN3aHFaZXlEbDFJZjVOUTdkeHNnMXlXeV9NeDdEZWNDeUJoZTVyd2FlR3VvR1B0Y2Z6QURkeGQ4SldPRDZkTzB6SXQ?oc=5","date":"2024-10-22","type":"pipeline","source":"European Medical Journal","summary":"Prioritising Patients and Planet: Advocating for Change in Respiratory Care - European Medical Journal","headline":"Prioritising Patients and Planet: Advocating for Change in Respiratory Care","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOVVVmOXZ3akk4TnRJeUxxejF0cFBQNXp6cGJYX0M4ZlBONGZKaGxUeW9UT0pOSjFnc3R5SzhpNHpZaks1dHhvSnBSQWdlSWhhY0pWUTZ3VTdEenFESFFxLWR4eFhSMi1FTEZXOV9nQTZiLXNsR2EwR2RFbW1tUWMwX2NYdlZ0SGlmWUh2MVR3c2UxY0YyZHAtd0dNQXhveXRlUzB3YndOdGRZRU42RlZrVzBQQ1pyYUhLUzZR?oc=5","date":"2024-09-17","type":"pipeline","source":"The Examination","summary":"In the US, opioid-maker Purdue is bankrupt. Its global counterparts make millions. - The Examination","headline":"In the US, opioid-maker Purdue is bankrupt. Its global counterparts make millions.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPNHJnZHFhYmpEZFQ0dHhfcUNLdS1rTEtxcGJfTHptbTE0b0NOQzZpVlhKYjVmQXVkNk5EQXl2UXVlZWJnWWNoSWZsSkxNX2tIaWk4cXRvRWlESDdoZ0wtR08xSUdQQ3d2SWQ0Skc3aF9tdFdmZ25DYW45dkpIXzNxbHJsQk1wOTJtTkd4Y2Y1UQ?oc=5","date":"2024-08-14","type":"pipeline","source":"SEC.gov","summary":"Document - SEC.gov","headline":"Document","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPMFJNbnA2VEYzeXFnMjZ6bUxBdmdTemRSc2RsNGoyZE1DczVLN2NrVXBZVm1YNEdIc3haRm5RajhMQTlBRW41RU1PRWJNbnRKbjNMMGRyYXpraHJBUkJobmJuSXlaOWR6eE45am9Fdy1MbTNCbTdJZk8xbXkyY1ZyTGFnYWJKdFdHU0tKMDdNRUgzVE5HWnNZdEE0d196RjQxc0V4WUdn?oc=5","date":"2021-09-02","type":"pipeline","source":"pharmaceutical-journal.com","summary":"Investigation: should liquid morphine be reclassified? - pharmaceutical-journal.com","headline":"Investigation: should liquid morphine be reclassified? - pharmaceutical","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPMnJXMTZUYWp5UkcyUXZxWXVxME9FVk95WEdzbFdkbHhuWkNDTW43eFZZX2xvSUJyTi1jTTFvSGdfeklnN2RKbmJkLWZ6b29WbWFSdGYwSkNEc1duQUdDREo5cE4zd0FhQTczczkxMjA0c3BqYjFpSjJ1blEtaFNDTjVhWXhDOFdYbnoySTd0RF8zeFBCM0duVHhxVFRjMkg2QWhPQQ?oc=5","date":"2019-05-26","type":"pipeline","source":"The Times","summary":"Hard sell marketing tricks behind US opioid crisis come to UK - The Times","headline":"Hard sell marketing tricks behind US opioid crisis come to UK","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOMHZwei1oVWVIczd6VldwRnNpdXJmakUtX0U2bW1raFpsVlRsTEkzQUY2anM2M2g2UFNVbm1EMVplRE9hRjdOX3pyeTRJSVV2NEM0dGlJbWNETzc0SFdzT2FFQVpCdzRxV0FlQU55Y01KbnpBLTFtSlJoUzU2SUpWN3BSby1COEthcHdaVXVsYmg1THU1cWxJ?oc=5","date":"2018-03-20","type":"pipeline","source":"PharmaTimes","summary":"Napp secures distribution rights to Celltrion’s Herzuma - PharmaTimes","headline":"Napp secures distribution rights to Celltrion’s Herzuma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNVHB3ZEt2WDRMdDlDeHFVVzNDY3dPMUQ2OFB3aUU3c1Nnb3FXeWRVVjdLbGszeER3WEpwQ21sLVE0ZmNYRFZRajU1bndIb1BtaWdxNTlqT3d5NVJlZ0ExVlhULS1sb2tFalpLSkVLTjdmQkhsWVcwc1NYUXNzYVpjQ2hmX2VOTWFWS3hFbw?oc=5","date":"2017-03-09","type":"pipeline","source":"PMLiVE","summary":"Hywel Day joins Napp Pharmaceuticals - PMLiVE","headline":"Hywel Day joins Napp Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPYzM4Vkw4QnhEeUNkR0lqS1Z4UDJJbk5FN292aW5kcWJXanRFNnNnM0dDREV5cGk1d0hSemZZRzRkUlZFTWNiRF9ENWQzTGY1cWZHRnRDdU5aWGhQQzZoT3RWckE1Nk1Rd1VORW5hOHZwUzE2al85U1h5dE1PT0JIOXU3UDUzN1ZJd1VwbTFaZi16enJMakE?oc=5","date":"2016-09-27","type":"patent","source":"European Pharmaceutical Review","summary":"Pharmaceutical patents: Clear the way but careful where you tread - European Pharmaceutical Review","headline":"Pharmaceutical patents: Clear the way but careful where you tread","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNd24zN2Z3NzZuY2R5VmJFY05EOHRXNjZXVFNQS1V0SmRyWE5tNHdIYnVxSTBZQmdLZC04Skd2c3Y5SGc0SXRobndrWWw0ZkVVQVkxNHg1azk2Rlo4Tlk2OTVHTDZTRC1fRXRCbXVhYUw4X3U3V3FTblV1WkJUbEFyQVVvSFRVbW5DYWhDZ3pDR25jdE52M0RDVkxBSFdEV3hzY2JrR2FDcGk?oc=5","date":"2012-01-31","type":"pipeline","source":"Pharmafile","summary":"Dietmar Leitner joins Napp Pharmaceuticals as its new managing director - Pharmafile","headline":"Dietmar Leitner joins Napp Pharmaceuticals as its new managing director","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}